Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Sep;8(18):1195.
doi: 10.21037/atm-20-3170.

The adjuvant regimen for resected EGFR mutated patients: the "same-for-all-therapy" or not?

Cesare Gridelli  1 , Francesca Casaluce  1
Affiliations
Editorial

The adjuvant regimen for resected EGFR mutated patients: the "same-for-all-therapy" or not?

Cesare Gridelli et al. Ann Transl Med. 2020 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-3170). CG, a speaker bureau and advisory board member, reports other from Astra Zeneca, other from BMS, other from MSD, other from Roche, outside the submitted work; FC has no conflicts of interest to declare.

Comment on

  • Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).
    Liang W, Cai K, Chen C, Chen H, Fang W, Fu J, Fu X, Gao S, Hu J, Huang Y, Jiang G, Jiao W, Li S, Li G, Li H, Li H, Li X, Liang N, Liu D, Liu H, Liu J, Liu L, Liu Y, Luo Q, Ma H, Mao W, Peng Z, Qiao G, Shao G, Tan L, Tan Q, Wang Q, Wang C, Wu Q, Xu S, Xu S, Xu L, Yang Y, Yu F, Zhang B, Zhang L, Zhao B, Zhi X, Brunelli A, Petersen RH, Liu CC, Ricciuti B, Metro G, Tuzi A, Suter MB, Evison M, Seki N, Sasada S, Izumo T, Cho WC, He J; written on behalf of National Clinical Research Center for Respiratory Disease; Thoracic Surgery Branch of China International Exchange and Promotion Association for Medical and Healthcare; Chinese Alliance Against Lung Cancer; AME Thoracic Surgery Collaborative Group. Liang W, et al. Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14. Transl Lung Cancer Res. 2019. PMID: 32010594 Free PMC article. Review. No abstract available.

References

    1. Liang W, Cai K, Chen C, et al. Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Transl Lung Cancer Res 2019;8:1163-73. 10.21037/tlcr.2019.12.14 - DOI - PMC - PubMed
    1. Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 2013;31:3320-6. 10.1200/JCO.2013.51.1816 - DOI - PMC - PubMed
    1. Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IBIIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 2015;33:4007-14. 10.1200/JCO.2015.61.8918 - DOI - PubMed
    1. Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/ CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018;19:139-48. 10.1016/S1470-2045(17)30729-5 - DOI - PubMed
    1. Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med 2018;6:863-73. 10.1016/S2213-2600(18)30277-7 - DOI - PubMed